Development and Imaging Validation of Fluorescent Lipid Nanoparticles for RNA Delivery Applicable to Personalized In Vitro Oncology Models

What is the context ?

The application of RNA vaccine technologies in cancer treatment holds great promise, though clinical effectiveness has yet to be fully demonstrated. To move forward, researchers need high-quality RNA production and encapsulation, along with accurate, cost-effective testing tools tailored to oncology research.

To meet this growing demand, Tebubio’s CRS laboratory offers RNA production and encapsulation services, delivering custom encapsulated RNA in microgram quantities. These materials are ideal for preclinical screening in areas such as vaccine development, therapeutic agent testing, and personalized medicine—for use by pharmaceutical companies, biotech firms, and academic researchers.

What is the poster about ?

Tebubio offers Contract Research Services (CRS) in RNA-based therapeutic discovery, in vitro modeling, biomarker mapping, and data analysis.

Leveraging these platforms, we have developed innovative lipid nanoparticles (LNPs) designed to monitor the RNA delivery. This advancement features a fluorescent lipid, synthesized by Echelon Inc., which enables imaging-based tracking of the LNPs. Using this fluorescent lipid, we formulated LNPs encapsulating fluorescent RNA.

We validated the distribution of these LNPs within mammalian cells and confirmed RNA expression in these cells through imaging techniques. This technology is applicable to in vitro oncology models, including patient-derived spheroids and tumoroids, which allow for a personalized approach to therapeutic testing. 

Ultimately, Tebubio’s platform provides end-to-end support, from RNA optimization and custom LNP formulation to efficacy validation in vitro, enabling personalized medicine models for RNA-based therapeutics.